https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00339
Currently, except for a partially protective vaccine against malaria, no vaccine is available for the rest of the Vector-borne protozoal diseases (VBPD), making epidemiological control and chemotherapy the main strategies. Available therapy faces problems such as reduced efficacy, toxicity and high costs. In addition, the development of new treatments is limited and no significant advances are anticipated. Integrated control adapted to each disease and region is required. To optimize the use of the scarce drugs available, it is crucial to improve surveillance, reporting accuracy and increase public and private investment.
